

Clinical research article

Full title: Levels of high-sensitive troponin T and mid-regional pro-adrenomedullin after COVID-19 vaccination in vulnerable groups: a prospective study on subtle and persistent cardiovascular involvement

Short running head: Cardiovascular biomarkers after COVID-19 vaccines

Authors: Martin Möckel¹, Samipa Pudasaini¹, Ngoc Han Le², Dörte Huscher³, Fabian Holert¹, David Hillus², Pinkus Tober-Lau², Florian Kurth², Leif Erik Sander^{2, 4}

Affiliations:

1 Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **2** Department of Infectious Diseases and Pulmonary Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **3** Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Campus Virchow-Klinikum and Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, 13353/10117 Berlin, Germany. **4** Berlin Institute of Health at Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

Corresponding author: Univ.-Prof. Dr. med. Martin Möckel, Charité – Universitätsmedizin Berlin (ORCID-ID: 0000-0002-7691-3709), Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charitéplatz 1, 13353/10117 Berlin, Tel.: +49(0)30-450-553203, E-Mail: martin.moeckel@charite.de.

Word Count: 6166 reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract:**

2 **Background:** This study examines potential, subtle and persistent adverse effects of COVID-19
3 vaccines on the cardiovascular system. Vaccine-associated myocardial injury was analysed by
4 measuring high-sensitive troponin T (hsTnT); mid-regional pro-adrenomedullin (MR-proADM) levels
5 were evaluated to assess endothelial dysfunction.

6 **Methods:** This was a prospective study with a vulnerable population of healthcare workers (HCWs)
7 and elderly patients (> 70 years) who were vaccinated with either one dose of ChAdOx1 nCov-19
8 adenoviral vector vaccine (AZ) followed by one dose of the BNT162b2 messenger RNA vaccine (BNT),
9 or with two doses of BNT (12th of January - 30th of November 2021). HsTnT and MR-proADM were
10 measured in blood samples at three visits (V₁: 1st immediately before vaccination; V_{2, 3}: 3-4 weeks
11 after 1st and 2nd vaccination). HsTnT of HCWs was compared to a healthy reference population.

12 **Results:** N=162 volunteers were included (V₁=161; V_{2, 3}=162 each). N=74 (45.7%) received AZ/BNT
13 and n=88 (54.3%) received BNT/BNT (elderly: n=20 (12.3%), HCWs: n=68 (42.0%)). Median hsTnT
14 levels were 4ng/L, 5ng/L and 4ng/L (V₁-V₃) for AZ/BNT and at 5ng/L, 6ng/L and 6ng/L (V₁-V₃) for
15 BNT/BNT. Compared to the reference population (n=300), hsTnT was significantly higher at all visits
16 for both vaccination groups (p<0.01), without differences between the AZ/BNT and BNT/BNT cohort.
17 MR-proADM values were 0.43nmol/L, 0.45nmol/L, 0.44nmol/L (V₁-V₃) in the AZ/BNT cohort and
18 0.49nmol/L, 0.44nmol/L, 0.47nmol/L for BNT/BNT, respectively. Change of median hsTnT and MR-
19 proADM between visits did not show significant increases. One HCW case had a permanent and
20 three a transient hsTnT increase ≥ 14 ng/L.

21 **Conclusion:** With one individual exception, no overall subtle, persistent cardiovascular involvement
22 was observed after the 2nd COVID-19 vaccination.

23

24 **Keywords:** COVID-19 vaccination; high-sensitive troponin T; persistent myocardial injury; mid-
25 regional pro-adrenomedullin; endothelial dysfunction.

26 **Introduction:**

27 Coronavirus disease 2019 (COVID-19) vaccines are generally safe and effective in reducing
28 the severity of SARS-CoV-2 infections and their complications (1, 2). About 70.6% of the world's
29 population has received at least one vaccine dose, and over 13 billion doses have been given
30 worldwide (3). To ensure the safety of COVID-19 vaccines, short- and long-term adverse events are
31 continuously monitored by active and passive pharmacovigilance and post-marketing studies and
32 vaccine safety is intensely studied (4, 5). The International Coalition of Medicines Regulatory
33 Authorities, representing 38 regulatory agencies, recently issued a joint statement on reassuring
34 safety data showing that COVID-19 vaccines have a very good safety profile in all age groups,
35 including children and people with underlying medical conditions (6). Rare adverse events include
36 complications of the cardiac system, like COVID-19 vaccine-associated myocarditis and pericarditis,
37 as well as adverse effects on the vasculature, such as an impaired endothelial function as well as
38 arterial and venous thrombosis (7-10).

39 COVID-19 vaccination and the cardiac system

40 Although rare, myo- and pericarditis are the most frequent adverse cardiac events following
41 COVID-19 vaccinations (11, 12) and were first reported in April 2021 (12). Today, incidence of myo-
42 and pericarditis is (region-specifically) estimated at 1 to 11 per 100,000 vaccinees (12, 13). Incidence
43 is highest among young adult males, particularly following the second dose of Moderna (MOD) or
44 BioNTech/Pfizer (BNT) messenger ribonucleic acid (mRNA) vaccine (12). In patients with mRNA-
45 vaccine related myo- and/or pericarditis, cardiomyocyte necrosis was almost always detectable, as
46 determined by measurements of the cardiac-specific biomarker high-sensitive troponin T (hsTnT) (14,
47 15). For instance, in a study by Oster *et al.*, elevated hsTnT was observed in 97.9% (792/809) of
48 COVID-19 vaccine-associated cases of myo- and/or pericarditis, as well as further major adverse
49 cardiac events (14). Hence, hsTnT measurement is of high relevance for the diagnostic identification
50 of patients with vaccine-related cardiac adverse events.

51 So far, cardiomyocyte injury in COVID-19 vaccine recipients was primarily analysed in study
52 populations that presented with clinically manifest and acute cardiac symptoms (7). Yet, it has rarely
53 been investigated if and to what extent a subtle, chronic post-vaccine myocardial involvement occurs
54 in a vaccinated population even in the absence of typical symptoms. Mainly three studies actively
55 monitored of hsTnT levels in a BNT-vaccinated cohort. Mansanguan *et al.* analysed 301 adolescents
56 of whom four had signs of a subclinical myocarditis, one suffered a clinically manifest myopericarditis
57 and two a pericarditis after the 2nd BNT162b2 vaccine. Here, cardiac biomarkers were measured at
58 baseline, day 3, 7 and 14 (optionally) (16). Levi and colleagues observed vaccine-associated
59 cardiomyocyte injury in two participants (0.6%), with one being symptomatic and one asymptomatic,
60 2 to 4 days after having received their 4th BNT dose (17). Lastly, Buergerin *et al.* detected the highest
61 rate of 2.8% (women: 20/777; men: 2/777) in their hospital employee cohort presenting with a
62 vaccine-induced myocardial injury on day 3 after receipt of MOD mRNA booster (18). All three
63 studies described cardiac involvement as mild and transient and mainly defined it as an acute hsTnT
64 elevation above the 99th percentile of upper reference limit (URL) (16, 18, 19). Electrocardiograms
65 and echocardiography were normal in the majority of affected participants (17, 18).

66 In order to further strengthen safety data and confidence in COVID-19 vaccines, additional
67 research is warranted to assess possible subtle and subclinical myocardial damage after COVID-19
68 vaccination, also with regards to varying vaccination regimens (vector versus mRNA or heterologous
69 vaccination). Furthermore, as emphasised in a recent editorial by Levi *et al.*, longitudinal
70 observations of hsTnT levels over time, e.g. including pre-vaccination status and follow-up samples
71 after booster vaccination, would be of interest to evaluate if any occurring subclinical cardiac injury is
72 likely self-limiting or becomes chronic (17).

73 COVID-19 vaccination and the vascular system

74 Mainly one study has investigated possible acute effects of COVID-19 vaccines on the
75 vascular system (20). The authors observed a short-term deterioration of endothelial function in the

76 first 24 hours after the 2nd BN vaccine dose. The extent of endothelial involvement was described as
77 far lower than in COVID-19, which in turn has been linked to endothelial cell infection and
78 endotheliitis (20). In COVID-19 patients, the biomarker mid-regional pro-adrenomedullin (MR-
79 proADM), an endothelium-related peptide with vasodilatory properties, was used to evaluate the
80 severity of endothelial dysfunction (21). Measurements of MR-proADM levels to assess possible
81 short- and long-term endothelial injury in COVID-19 vaccine recipients have not been analysed so far.

82 Study focus

83 By conducting a prospective observational study, we investigated subacute, subtle, and
84 subclinical cardiomyocyte injury in two risk populations with follow-ups until 4 weeks (optionally
85 longer) after completion of the original COVID-19 basic vaccination regimen. We hypothesize that
86 hsTnT levels remain unchanged during follow-up, indicating no significant rise in myocardial injury in
87 the short- and long-term compared to baseline. Secondly, we sought to analyse endothelial function
88 based on levels of MR-proADM throughout the study period. With these two approaches, we aimed
89 to address current knowledge gaps concerning chronic cardiovascular effects of COVID-19
90 vaccination.

91 **Methods:**

92 Study design and study population:

93 The participants were recruited within the multicentre prospective observational studies,
94 EICOV, COVIMMUNIZE and COVIM and consisted of health care workers (HCWs) of Charité –
95 Universitätsmedizin Berlin as well as elderly/senior patients (> 70 years) at a general practitioner’s
96 office in Berlin, Germany; two different types of risk populations in the pandemic. While vulnerability
97 of HCWs is caused by their regular exposition to infectious patients, elderly mainly fall into this
98 category due to their compromised immune response and multi-morbidity (22, 23). All participants
99 received their first two COVID-19 vaccinations between 12th of January and 22nd of June 2021 with
100 either a combination of AZ (AstraZeneca)/BNT (only for HCWs) or BNT/BNT (HCWs or elderly).

101 Booster vaccinations (3rd and 4th) were only mRNA-based (BNT or MOD). Key inclusion criteria were
102 the ability to give written informed consent by the participants or via their legal representative, no
103 contraindications to receiving a COVID-19 vaccination and an age of ≥ 18 years at the time of
104 enrolment.

105 Three main visit timepoints (V₁-V₃) were conducted. V₁: at baseline, i.e., 7 to 0 days before the 1st
106 vaccination; V₂: 3-4 weeks after the 1st vaccination and V₃: 3-4 weeks after the 2nd vaccination (Figure
107 (Fig.) 1). Prior work on this topic has shown that cardiovascular biomarkers, if elevated in the acute
108 setting, usually rise and fall within 1-2 weeks after vaccinations. By choosing an interval of 3-4 weeks
109 post-vaccination for biomarker measurement, we aimed to assess subacute or persistent hsTnT
110 elevation (16). Participants that opted to participate in the follow-up study COVIM-Boost, a 4th visit
111 (V₄) and 5th visit (V₅) was captured and is reported here for HCWs as part of an ancillary analysis up to
112 50 days after the 3rd and 4th vaccination (with either BNT or MOD), respectively (Supplementary Fig.
113 1). At all visits, serum and ethylenediaminetetraacetic acid (EDTA) blood samples were collected. MR-
114 proADM was measured in EDTA plasma [nmol/L] on the Kryptor Compact Plus device (Thermo Fisher
115 Scientific, Waltham, MA, USA). The clinically relevant cut-off was set at ≥ 0.75 nmol/L (24).
116 Depending on the sample availability, EDTA or serum samples were used for measuring hsTnT (via
117 Cobas e801, Roche Diagnostics, Mannheim, Germany). In the diagnostic exclusion procedure of a
118 myocardial infarction, relevant hsTnT levels are defined as being $>$ the 99th percentile of URL (25).
119 This definition was also adopted by prior studies with a research question similar to ours (16-18).
120 However, in a study by Barbier *et al.* the authors pointed out that new, subclinical cardiomyocyte
121 injury, detected in late enhancement magnetic resonance imaging, may only be reflected in minor
122 troponin elevations (of 4.1ng/L to 5.9ng/L) and slight increases also correlate with a negative
123 prognosis (26). Additionally, in cases of SARS-CoV-2 infections with cardiac involvement,
124 troponinemia was likewise mostly mild (27). Therefore, to also capture a possibly subtle but relevant
125 troponin increase, we focused on all changes in hsTnT levels in the course of the visits and put it in
126 relation to the initial baseline hsTnT value of the respective participant. Cases with a hsTnT elevation

127 > the 99th percentile cut-off value were presented and interpreted separately. HsTnT levels below the
128 limit of detection (3ng/L), were set to 2.9ng/L for analyses.

129 Demographic and clinical characteristics of all participants, including age and sex,
130 comorbidities and pre-medication were collected at enrolment and used for comparison with the
131 reference cohort.

132 Reference population:

133 As a reference population, participants of the BIC-1 (**B**iomarkers in **C**ardiology **1**) study were
134 used. This included HCWs of Charité – Universitätsmedizin Berlin that were recruited between 6th of
135 July 2007 and 5th November 2007. Clinical exclusion criteria were the presence of a heart failure,
136 other heart diseases, kidney or metabolic diseases and the intake of permanent medication.
137 Therefore, this cohort was defined as a presumably healthy reference and was used for comparison
138 of hsTnT values with our HCWs in the vaccination groups. Further inclusion criteria include a full
139 employment contract, age of 18 years or older and no direct dependence on the study leader were
140 required for inclusion. In this cohort, one visit (V_{R-1}) was performed. HsTnT was measured in lithium-
141 heparin blood samples on the same analyser module as in our vaccination cohorts (Cobas e801,
142 Roche Diagnostics, Mannheim, Germany).

143 Hypothesis:

144 The primary hypothesis was that the distribution of hsTnT remains unchanged across all
145 vaccination groups at the visits V_1 to V_3 . Therefore, we assumed that neither the combination of
146 AZ/BNT, nor the BNT/BNT scheme would lead to a significant elevation of hsTnT compared to
147 baseline levels at enrolment visit V_1 . Secondly, we expected no relevant chronic endothelial
148 dysfunction to be detected in the sense of a significant median difference between V_1 to V_3 of
149 MRpro-ADM values in the observed time span.

150

151 Statistical analysis:

152 A basic description of the vaccination and reference groups was performed, including characteristics
153 of sex, age, Body-Mass-Index (BMI), smoking status, comorbidities, and pre-medication at enrolment.
154 If not indicated otherwise, metric values are presented as median with the associated interquartile
155 range (IQR). Due to the skewed distribution of hsTnT and MR-proADM values, non-parametric tests
156 were performed. The Mann-Whitney U test was applied to test the difference of hsTnT and MR-
157 proADM levels between the vaccination groups, and the Wilcoxon signed rank test to investigate
158 individual change between the visits for both biomarkers (differences V_2-V_1 , V_3-V_1 , V_3-V_1). Correlation
159 analyses were performed separately for sex between hsTnT and MR-proADM at each visit, and for
160 both hsTnT and MR-proADM with age at V_1 . Spearman's correlation coefficients were reported.
161 Comparisons of hsTnT values between the reference group and the two vaccination cohorts (solely
162 HCWs included here) were performed with the Kruskal-Wallis-test and pairwise post-hoc tests with
163 Bonferroni correction. Mixed-effects models were calculated to examine effects of age (per 10
164 years), sex, and the type of COVID-19 vaccination on the course of hsTnT and MR-proADM values,
165 with random effects for the intercept. Since most visits were performed within a very close time
166 window, the course of hsTnT and MR-proADM values were further explored in mixed-effects
167 regression models treating the visits as repeated measurements, again including random effects for
168 the intercept. In addition, mixed-effects regression models for propensity score-matched groups
169 were calculated to examine effects of the vaccinations while controlling for potential confounders.

170 All analyses were performed using IBM SPSS Version 29 (IBM Corporation, Armonk, NY, USA)
171 and R version 4.3.1 (2023-06-16 ucrt). A p-value <0.05 was considered significant; for pairwise
172 subgroup comparisons or parallel tests in visits V_1 to V_3 , p-values were adjusted for multiple testing.

173 Ethical approval and study registration:

174 The COVIM study (EA4/245/20), its preceding studies EICOV (EA4/245/20) and
175 COVIMMUNIZE (EA4/244/20), the follow-up study COVIM-Boost (EA4/261/21) and the BIC-1 study

176 (EA2/030/07) were approved by the ethics committee of Charité – Universitätsmedizin Berlin. BIC-1
177 was registered in the German register for clinical studies (DRKS-ID DRKS00000310) and COVIM in the
178 European clinical trial register (EudraCT-2021–001512–28).

179 **Results:**

180 Characteristics of the study population:

181 Information on basic characteristics is provided in Table (Tab.) 1. In total, the study
182 population consisted of 162 people in the vaccination group, including 142 (87.7%) HCWs and 20
183 (12.3%) elderly patients (solely in the BNT/BNT group). Except for one person who missed the 1st
184 visit, all participants were seen (at least) three times. Altogether, 74 (45.7%) participants received the
185 combination of AZ/BNT, while 88 (54.3%) participants were vaccinated according to regular BNT/BNT
186 regimen. In the AZ/BNT group, 41 (55.4%) participants and in the BNT/BNT population 49 (55.7%)
187 were female, respectively. The median age was 33.2 years in the AZ/BNT and 37.6 years in the
188 BNT/BNT group. Median BMI was 23.9 kg/m² and 23.8 kg/m², respectively. Out of 148 available
189 answers, 16 reported being either former current smokers.

190 [Position of Figure 1]

191 With regards to pre-medication, 9 (5.6%, 7/9 from the BNT/BNT cohort) reported receiving
192 immunosuppressive therapy and 4 (2.5%, 3/4 from the BNT/BNT group) participants reported taking
193 corticosteroids at enrolment. Furthermore, 14 (8.6%) participants reported taking antihypertensive
194 drugs, 3 (1.9%) anticoagulants and 4 (2.5%) antiplatelet drugs as a permanent medication, the
195 majority of participants on this medication belonging to the elderly group (see Tab. 1.)

196 Four (5.4%) participants in the AZ/BNT cohort, and 17 (19.3%) participants in the BNT/BNT
197 cohort reported a cardiovascular disease at baseline, with hypertension (AZ/BNT: 4/74 (5.4%);
198 BNT/BNT: 16/88 (18.2%)) as the most frequent condition. Chronic lung diseases were present in 10
199 (6.2%) participants, with 4 (5.4%) being in the AZ/BNT and 6 (6.8%) participants in the BNT/BNT
200 cohort. Other comorbidities, with 7 cases each (4.3%), included kidney disease (6/7 BNT/BNT),

201 rheumatologic/immunological diseases (4/7 BNT/BNT), and cancer (5/7 BNT/BNT). Diabetes,
202 dementia, cerebrovascular or chronic haematological diseases were present in 5 (3.0%) cases, or less.

203 Characteristics of the reference population

204 The reference population included 300 individuals with a 1:1 female to male ratio. The
205 median age was 39.0 years. For all 300 participants, hsTnT values were available at V_{R-1} for analysis.
206 Comorbidities and pre-medication are not reported for this cohort since both were exclusion criteria
207 (Tab. 1).

208 [Position of Table 1]

209 HsTnT measurement:

210 The median values of hsTnT in the AZ/BNT group were 4ng/L (IQR 4-6), 5ng/L (IQR 4-6) and
211 4ng/L (IQR 4-6) for V_1 , V_2 , V_3 , and for the BNT/BNT cohort 5ng/L (IQR 4-8), 6ng/L (IQR 4-9) and 6ng/L
212 (4-8.5), respectively. Separated by HCWs and elderly (BNT/BNT), the seniors showed higher median
213 values of 18ng/L (IQR 11-29), 15ng/L (IQR 10.5-25.5) and 13.5ng/L (IQR 10-22.5) during follow-up
214 visits. HsTnT levels at V_1 - V_3 in the AZ/BNT group were lower compared to the BNT/BNT cohort, at all
215 visits, including at baseline ($p_{V1}=0.048$, $p_{V2}=0.003$, $p_{V3}<0.001$). The individual progression for V_1 - V_3 is
216 visualised in Fig. 2A, separated by vaccination regimen and sex. Median hsTnT in the reference
217 population was 3.6ng/L (IQR 3.0-4.9, Fig. 3). For all HCWs, median hsTnT values were higher in males
218 at all visits, including baseline (V_1 : $p=0.010$; V_2 : $p=0.003$; V_3 : $p=0.006$). Changes of median hsTnT
219 values were 0ng/L (IQR -1.0 to 1.0; V_2 - V_1), 0ng/L (IQR -1.0 to 0.0; V_3 - V_2) and 0ng/L (IQR -1.0 to 0.0; V_3 -
220 V_1) in the AZ/BNT cohort (Fig. 2B). In the BNT/BNT population, changes were 0ng/L (IQR 0.0 to 1.0;
221 V_2 - V_1), 0ng/L (IQR -1.0 to 1.0; V_3 - V_2) and 0ng/L (IQR -1.0 to 1.0; V_3 - V_1). There were no individual
222 differences of hsTnT levels between all visits (AZ/BNT: V_2 - V_1 $p=1.0$; V_3 - V_2 $p=0.25$; V_3 - V_1 $p=0.42$;
223 BNT/BNT: V_2 - V_1 $p=0.24$; V_3 - V_2 $p=0.25$; V_3 - V_1 $p=1.0$). Median changes of hsTnT for HCWs and elderly of
224 the BNT/BNT cohort separately showed significant differences between V_2 and V_1 for HCWs (median

225 0 ng/L (IQR 0.0 to 1.0), $p=0.029$) and between V_3 and the two prior visits for elderly (V_3-V_2 : median -1
226 ng/L (IQR -4.0 to 0.0), $p=0.038$; V_3-V_1 : median -2ng/L (IQR -4.0 to 0.0), $p=0.008$) were visible (Fig. 2C).

227 Four HCW cases stand out regarding their individual hsTnT levels and are therefore be
228 reported separately in detail (Fig. 2A). One BNT/BNT participant (“w”, male, in his 30s, HCW) showed
229 a steady hsTnT rise with values of 15ng/L, 21ng/L and 25ng/L (V_1-V_3). At enrolment, he reported
230 having had muscle pain and fever in the 7 days prior. At a follow-up visit 6 months after V_1 , he stated
231 having suffered from headache in the 7 days before presenting. Generally, no pre-existing medical
232 conditions were reported by this participant. A second participant “x” (male, in his 20s, HCW,
233 BNT/BNT), had a noticeable but transient hsTnT elevation at V_2 and normalised again at V_3 (7ng/L,
234 17ng/L, 5ng/L). He reported the following baseline conditions: hypertensive heart disease, ulcer
235 duodeni and vascular encephalopathy. Secondly, in the AZ/BNT population, two participants
236 presented with a transient hsTnT elevation (participant “y” (male, in his 20s): 8ng/L, 14ng/L, 5ng/L;
237 participant “z” (male, in his 20s): 6ng/L, 17ng/L, 6ng/L). Both did not report any symptoms, pre-
238 medication or comorbidities.

239 In total, 16 study participants had at least one absolute hsTnT value > the 99th percentile of
240 URL. Out of these, four participants presented with a normal baseline hsTnT value, while the other 12
241 participants showed levels of ≥ 14 ng/L already at enrolment, prior to COVID-19 vaccination (Fig. 2A).

242 [Position of Figure 2]

243 Comparison of hsTnT levels in HCWs in the study cohort to HCWs in the reference cohort:

244 HsTnT levels in the reference cohort were significantly lower than in the AZ/BNT and
245 BNT/BNT group at all three time points (at V_1 and V_2 compared to both vaccination groups: $p<0.001$;
246 at V_3 : for V_{R-1} -AZ/BNT: $p<0.001$ and for V_{R-1} -BNT/BNT: $p=0.006$) (Fig. 3).

247 [Position of Figure 3]

248

249 MR-proADM measurement:

250 The MR-proADM median value was 0.43nmol/L (IQR 0.39-0.47), 0.45nmol/L (IQR 0.39-0.50)
251 and 0.44nmol/L (IQR 0.38-0.52) (V_1 - V_3) in the AZ/BNT population. In the BNT/BNT group, median MR-
252 proADM levels were 0.49nmol/L (IQR 0.42-0.63), 0.44nmol/L (IQR 0.40-0.55) and 0.47nmol/L (IQR
253 0.41-0.64), respectively (Fig. 4A). The comparison of MR-proADM between the vaccination groups
254 revealed a significant difference at V_1 and V_3 (V_1 : $p<0.001$; V_2 : $p=0.336$; V_3 : $p=0.032$). Generally, 17
255 participants (AZ/BNT: $n=2$; BNT/BNT: $n=15$) had at least one MR-pro ADM value > 0.75 nmol/L.
256 Median changes of MR-proADM levels between the visits V_1 and V_2 were 0.01nmol/L (IQR -0.02 to
257 0.06; AZ/BNT) and -0.02nmol/L (IQR -0.05 to 0.02; BNT/BNT), with a small but significant difference
258 between the vaccination groups ($p=0.014$). Between V_2 and V_3 median values differed at -0.02nmol/L
259 (IQR -0.05 to 0.04; AZ/BNT) and 0.01nmol/L (IQR -0.06 to 0.06; BNT/BNT) and median changes
260 between the study visits V_1 and V_3 were 0.01nmol/L (IQR -0.03 to 0.06; AZ/BNT) and 0.00nmol/L (IQR
261 -0.05 to 0.04; BNT/BNT), without statistical significance (Fig. 4B, C). One participant presented with a
262 striking rise in MR-proADM levels during the study course (BNT/BNT group, in his 80s, male; V_1 :
263 1.1nmol/L, V_2 : 1.1nmol/L, V_3 : 1.5nmol/L) (Fig. 4A). He reported one cardiovascular comorbidity
264 (hypertension) as well as an active cancer disease (Hodgkin lymphoma).

265 [Position of Figure 4]

266 Correlation models:

267 Correlation between hsTnT and MR-proADM values was assessed for all three visiting times
268 (Suppl. Fig. 4A). The Spearman's correlation coefficient was low in both males (V_1 : $r=0.36$; V_2 : $r=0.08$;
269 V_3 : $r=0.38$) and females (V_1 : $r=0.55$; V_2 : $r=0.32$; V_3 : $r=0.57$), with a tendency to even lower
270 correlation at V_2 . A stronger correlation was seen between hsTnT levels and age (female: $r=0.69$;
271 male: $r=0.45$) as well as MR-proADM and age (female: $r=0.67$; male: $r=0.56$) in female participants
272 (Suppl. Fig. 4B and C).

273

274 Mixed-effects models:

275 Mixed-effect models were calculated for HCWs to identify factors that are associated with
276 MR-proADM and hsTnT values over time, with the first vaccination as the anchor defining time 0 (Fig.
277 2A, 4A). Sex, age (per 10 years), and the type of COVID-19 vaccine were used as independent
278 variables. Results showed a significant effect of male sex and increasing age, but not the type of
279 vaccine on both hsTnT and MRproADM levels. There was no linear effect over time, but when
280 ignoring shifts in time of lab measurements relative to the first vaccination and treating the visits as
281 repeated measurements, only V_2 showed a significant increase compared to V_1 with 0.41 ng/L (95%CI
282 0.12 to 0.70, $p=0.005$); no difference between V_3 and V_1 ($\beta=0.13$ ng/L, 95%CI -0.15 to 0.42, $p=0.356$)
283 was detected. When considering interaction, there was no interaction between this time effect and
284 the type of vaccination, with the general time effect disappearing. For MRproADM, no significant
285 effects except for age were seen (Tab. 2). In addition, mixed-effects regression models for propensity
286 score-matched groups were utilised. 69 pairs were found per vaccination group and matched. Also
287 here, no significant differences between the vaccination schemes were seen for both biomarkers.
288 Results on this are presented in Supplementary Tab. 1.

289 [Position of Table 2]

290 Ancillary analysis:

291 In our follow-up study COVIM-Boost, a part of the participants of the original study were
292 visited after booster vaccination (i.e. 3rd and 4th vaccination). Visits V_4 and V_5 are reported, if
293 performed between 3-4 weeks after the vaccination and up to a maximum of 50 days afterwards.
294 Altogether in HCWs, 25 3rd vaccinations and visits at V_4 were registered while the 4th vaccination was
295 applied to 12 people in total with 9 registered V_5 visits. Details are listed in Supplementary Fig. 1.
296 HsTnT median levels were 4 ng/L (V_4) and 3 ng/L (V_5), while median MR-proADM values were 0.46
297 nmol/L (V_4) and 0.54 nmol/L (V_5). The hsTnT and MR-proADM progression for all visits V_1 to V_5 are
298 visualised in Supplementary Fig. 2A and 3. Furthermore, we performed a post SARS-CoV-2

299 breakthrough infection measurement of hsTnT and MR-proADM up to 50 days after the infection.
300 Participants with a reported breakthrough infection during the study course are marked in orange
301 (Supplementary Fig. 2B).

302 **Discussion**

303 In this prospective observational study, we assessed if subtle, subacute and persistent
304 myocardial involvement is detectable in a vulnerable population of HCWs and elderly patients
305 following basic vaccination against COVID-19 with either an AZ/BNT or a BNT/BNT vaccination
306 regimen. With the approach of an active surveillance, the biomarkers hsTnT and MR-proADM were
307 measured at enrolment and at 3-4 weeks after the 1st and the 2nd vaccination, respectively.

308 *HsTnT levels after COVID-19 vaccination*

309 Regarding baseline hsTnT values (V_1), the HCW vaccination cohort had a median hsTnT level
310 of 4-5ng/L (IQR 4-6), whilst the reference population presented with a slightly lower median of
311 3.6ng/L (IQR 3.0-4.9). As visible in our post-hoc pairwise comparisons, this difference in hsTnT at V_1
312 was significant. As V_1 was performed before or right at the time of the 1st vaccination, this difference
313 in baseline hsTnT values must be viewed as an indicator of pre-existing differences in patient
314 characteristics. For instance, this observation may be explainable by the fact that the reference
315 cohort did not include any participants with cardiological, nephrological or endocrinological diseases
316 and were, therefore, presumably healthy, whilst in our study cohort, pre-existing diseases were not
317 an exclusion criterion. Therefore, our results underline that the HCW cohort, if not preselected
318 otherwise, represent a cohort that is working in health care, is <65 years of age, but that is otherwise
319 not free of pre-existing illnesses. Furthermore, hsTnT values in our BNT/BNT senior group were
320 comparatively high with a median of 18ng/L (IQR 11-29), with 10 out of 20 elderly participants
321 already having an elevated hsTnT level above the 99th percentile of URL at baseline V_1 . This is in
322 accordance with common literature, indicating that increasing age accounts for higher troponin
323 levels (28, 29), either as an independently increasing variable and/or as a sign for an underlying

324 (silent) disease, and this was also reproduced in our correlation analysis. For instance, Orlev and
325 colleagues reported a median hsTnT at 14ng/L in nursing home patients at an age of >70 years even
326 though the study population was described as asymptomatic (28). Self-evidentially, when discussing
327 slight troponin differences, analytical imprecision of hsTnT measurement, especially in values below
328 the 99th percentile of URL, must also be considered, besides the mentioned biological variability (30,
329 31).

330 With regards to hsTnT time kinetics, median hsTnT values of all participants remained almost
331 stable at 5ng/L for V₁, V₂ and V₃. When specifically analysing the vaccination cohorts stratified by
332 vaccine type and age, BNT/BNT elderly and BNT/BNT HCWs, changes of median hsTnT over time
333 were partially statistically significant, however, median absolute differences were still at 0ng/L for
334 HCWs, indicating that these changes are not of clinical relevance. For the elderly, absolute changes
335 were -1 ng/L and -2 ng/L, when comparing visit 3 to the prior visits, indicating, if anything, rather a
336 slight post-vaccination decrease. In the group of medical personnel, four male participants stood out
337 with a pronounced troponin elevation. All of them were young to mid-aged males, fitting to the
338 typical group of vaccine recipients with rare vaccine-related myo- and/or pericarditis (12). Participant
339 “w” who showed a transient hsTnT rise to 17ng/L at V₂, did not report any corresponding symptoms.
340 He had a prior known hypertensive heart disease. Here, the troponin elevation could be interpreted
341 as a typical transient, subclinical myocarditis but without chronic residuals. Participant “x” presented
342 with a steady increase in hsTnT levels up to 25ng/L at V₃. However, no cardiovascular comorbidity
343 was stated by him before enrolment. Therefore, the increase in hsTnT may either be a result of a yet
344 unknown underlying cardiac disease and/or it may be interpreted as a subtle post-vaccine myocardial
345 injury. The same hypothesis is assumed for persons “y” and “z”. In all cases, the hsTnT elevation was
346 already detected after the 1st BNT vaccination (V₂) and hsTnT elevation was transient in all cases
347 except for one. Those with a transient hsTnT rise, returned to baseline levels or lower. The similar
348 incidence of cardiac injury biomarker elevation following mRNA- and vector vaccines, is not in
349 agreement with prior studies showing cardiomyocyte injury primarily after mRNA vaccination (12).

350 Also, our findings partly deviate from the literature, which reported rare cardiomyocyte damage in
351 the context of myocarditis and/or pericarditis, mainly after the 2nd vaccine dose (12). When taking a
352 look at the individual median troponin values of the BNT/BNT vaccinated elderly, it is noticeable that
353 all 10 seniors with high absolute hsTnT levels in the course of the study period (V₂, V₃), already
354 showed a relevant troponin elevation of $\geq 14\text{ng/L}$ at the enrolment visit. Apart from this, no relevant
355 vaccine-induced additional hsTnT elevation was detectable until V₃ amongst the elderly cohort.
356 Therefore, our results support the notion that no overall subtle, subacute cardiomyocyte injury can
357 be observed in this prospective cohort in temporal relation to the performed COVID-19 vaccinations.
358 This appears to be the case irrespective of vaccination regimen, as indicated by our pairwise
359 comparisons that showed no significant differences of hsTnT levels between the AZ/BNT and
360 BNT/BNT groups (HCW sub-group) at V₁ to V₃.

361 Existing studies on hsTnT and myocardial injury were so far performed either on HCWs or
362 adolescents (16-18). Thus, mainly previous studies are comparable to the hsTnT results of our HCW
363 sub-cohort, since the baseline characteristics of our elderly group differ strongly. Mansanguan and
364 colleagues reported a relevant cardiac biomarker elevation in 7/301 (2.3%) cases, including 5 (1.6%)
365 with cardiac troponin T $\geq 14\text{ng/L}$ out of which 4 (1.3%) were described as occurrences of subclinical
366 myocarditis with initially normal hsTnT levels, followed by a post-vaccine elevation that peaked at
367 day 7 (16). These participants were between 13 to 17 years old; an age range that was not covered in
368 our work, but according to the literature, includes most of the post-COVID-19-vaccine-associated
369 myocarditis cases (12). However, for those 4 adolescents with subclinical troponin elevations, the
370 researchers did not provide follow-up measurements at day 14 (16). Therefore, it is not possible to
371 evaluate whether troponin elevations persisted or declined with time. In general, study objective,
372 participant age and observation span differed largely from our work, making a direct comparison
373 difficult. Regarding participant characteristics, our cohort is most similar to the one studied by Levi *et*
374 *al.* who recruited 324 HCWs of whom 22 showed a hsTnT above the sex-specific 99th percentile at
375 baseline and 27 showed elevated hsTnT within 2-4 days post-vaccination (4th BNT162b booster) (17).

376 However, the authors primarily focused on 2 participants who additionally showed a hsTnT rise of >
377 50% compared to enrolment measurements and interpreted this as vaccine-related myocardial
378 injury; both did not have a clinical myocarditis (17). A detailed characterization of the remaining
379 HCWs with slightly elevated hsTnT would have also been of interest but was not provided in the
380 publication. In contrast, we focused not only on hsTnT elevations above the URL and exceeding the
381 reference change value, since slight elevations below the 99th percentile can, in the long term, also
382 impact clinical outcomes (26). Our results differ from those of Buergin *et al.* who reported a mild and
383 transient cardiomyocyte injury in a significantly higher proportion of participants in their cohort of
384 hospital employees (2.8%; 22/777) 3 days after mRNA-1273 booster vaccination, with mainly female
385 HCWs (2,57%; 20/777) being affected (18). This difference in sex distribution was not reproducible in
386 our study. As described above, individual cases of a noticeable troponin rise were solely observed in
387 male participants and, overall, median hsTnT levels, separated by sex, were significantly higher for
388 our male population at all main visiting points. Also, the comparatively high cases of troponin
389 elevation deviate from our results. However, here, it must be kept in mind that our first post-
390 vaccination visit (V₂) was performed up to 4 weeks after vaccination, with the aim of capturing
391 persistent myocardial involvement. Therefore, our data does not allow for conclusions on possible
392 acute troponin changes that may have occurred within the first days after vaccination. Yet, since
393 other studies by Mansanguan *et al.* and Levi *et al.* did not find much lower incidences of myocardial
394 injury in the immediate post-vaccine period (16, 17), possible other reasons for the deviating results
395 of Buergin *et al.* must be considered. On the one hand, the authors chose the respective sex-specific
396 URL, which was for females at 8.9ng/L and, therefore, clearly lower than 14ng/L (18). On the other
397 hand, the distribution of sex was unbalanced in their study with an approximately 1:2 ratio of
398 males:females (18). This difference in selection may have consequently resulted in higher numbers of
399 cases with positive troponin amongst females than compared to prior trials. Further, Levi *et al.*
400 discussed a higher immunological response, and subsequent cardiac involvement, observed after the
401 former BNT1273 vaccination, contrasting to BNT162b2, as a plausible reason for the increased rate of

402 troponin elevations (19, 32). Our study only investigated AZ or the BNT162b vaccine, which may also
403 account for lower hsTnT levels. Importantly, one crucial limitation of Buerger and colleagues' study
404 was the missing baseline assessment of hsTnT levels (18). Elevated troponin levels may therefore
405 have existed prior to vaccination and must, thus, be interpreted with caution.

406 MR-proADM levels after COVID-19 vaccination

407 MR-proADM is a biomarker for endothelial dysfunction and can be elevated for a broad
408 spectrum of causes. Its release can be related to ongoing infectious processes, which is why MR-
409 proADM is used as a prognostic marker for sepsis patients, including for cases of severe COVID-19
410 (20, 21), but also heart failure (24). Especially in the early stages of the pandemic, COVID-19 was
411 discussed as a disease mainly affecting the vascular system (33). However, a vaccine-associated
412 endothelial dysfunction has been rarely investigated and, if so, predominantly in the acute post-
413 vaccination phase (20). Therefore, this study is the first of its kind in which MR-proADM
414 measurements were performed to assess persistent endothelial damage.

415 At baseline, the median MR-proADM was 0.44nmol/L for the whole study population and
416 ranged between 0.43 and 0.49nmol/L in the AZ/BNT group and HCW-BNT/BNT sub-cohort; i.e. below
417 the clinical cut-off of 0.75nmol/L for all HCWs. In the elderly group, a higher median MR-proADM of
418 0.95nmol/L was observed at V₁. Accordingly, a significant difference in median MR-proADM levels
419 was detected when comparing the HCWs and elderly groups; both at enrolment visit V₁ and at V₃. It
420 can be assumed that these differences are mostly driven by known age-dependent, naturally higher
421 values in the senior BNT/BNT sub-group. Furthermore, cardiovascular disease was reported in 70% of
422 the elderly. From prior literature, we know that MR-proADM remains stably elevated in patients with
423 pre-existing cardiovascular conditions (34). Focusing on the two younger and healthier HCW cohorts,
424 no significant differences were detectable at any of the study visit. Moreover, changes in absolute
425 median MR-proADM levels over time were nearly zero. Overall, 17 participants presented with at
426 least one MR-proADM value above the clinical cut-off during the course of the study; however, 15 of

427 them had elevated values already at enrolment, indicating that MR-proADM elevation was
428 independent of vaccination. One case stood out because of a steep MR-proADM increase from visit
429 V_2 to V_3 . However, considering that the participants suffered from an active haematological
430 malignancy MR-proADM levels may be related to the underlying condition and were interpreted as a
431 non-vaccine associated effect. The remaining participants showed no relevant kinetic and/or a return
432 to baseline levels at V_3 . Therefore, our data indicate no evidence of subacute or persistent post-
433 COVID-19 vaccination endotheliitis, based on MR-proADM measurements. This is in line with the
434 results a previous study by Terentes-Printzios *et al.* who reported no signs of permanent endothelial
435 dysfunction after the COVID-19 vaccination by measuring, among other markers, brachial artery-flow
436 mediated dilatation (20). However, this study reported a transient endothelial impairment in the
437 immediate 24 hours after vaccination (20); a time point that was not covered in our studies.

438 Association between hsTnT and MR-proADM levels as analysed by Spearman's correlation
439 were low for both females and males at all visiting times. A prior study by Theuerle *et al.* reported
440 that MR-proADM may also function as a marker for myocardial damage and strong correlations
441 between MR-proADM and hsTnT were discussed, without a further sex-dependent analysis. The
442 researchers emphasised that a combined positive biomarker assay may be associated with a higher
443 death risk in septic patients (35). While this may well be the case in severely ill patients with
444 significant cardiovascular damage, our data suggest that hsTnT and MR-proADM correlation is weak
445 in healthier cohorts with only have mild biomarker elevations.

446 Strengths and Limitations

447 This is a prospective observational cohort study, in which we performed three study visits to
448 assess persistent myocardial and vascular damage after the COVID-19 vaccination. The comparatively
449 low sample size limits the statistical power and generalizability of the results. In this context, it must
450 be acknowledged that the present work was conducted during the ongoing worldwide COVID-19
451 pandemic; a period characterised by significant political, social as well as research- and healthcare-

452 related turbulence. Thus, the planning and execution of such a study within a constrained timeframe,
453 involving vaccine-naïve individuals was challenging and the number of participants difficult to
454 regulate. Therefore, a certain validation in larger cohorts may be required in the future. However,
455 the availability of baseline values and a reference cohort is a major strength over other existing and
456 possible future studies, since it allows the characterization of vaccine-associated elevation of
457 biomarkers as compared to baseline and their trajectory over time. At the same time, since time
458 span between V_1 to V_3 was several weeks, the data cannot definitively prove a causative association
459 between COVID-19 vaccination and elevated markers of acute cardiovascular damages. Another
460 limitation is the slightly distinct demographic baseline characteristics of the reference cohort and the
461 study population, and the lack of available MR-proADM data for the reference cohort. Another
462 strength of our work is the fact that the study included the 1st COVID-19 vaccine dose, and also
463 compared two different vaccination regimens, which allowed for a broad and longitudinal analysis of
464 cardiovascular effects of COVID-19 vaccinations. By analysing all troponin changes, regardless of
465 clinical symptoms and regardless of their absolute level above or below clinical cut-offs provides data
466 also on potentially mild subclinical adverse effects of COVID-19 vaccines. In addition, to our
467 knowledge, this is the first study that included an elderly sub-cohort and compared it to a young to
468 mid-aged cohort. This is significant, since COVID-19 vaccinations are highly effective and most
469 beneficial with regards to preventing severe diseases and mortality in older risk patients, most of
470 which present additional with pre-existing conditions.

471 Conclusion and clinical outlook

472 This study shows no relevant hsTnT and MR-proADM increase in temporal association with
473 COVID-19 vaccination in our cohort. Although the sample size is limited, the cohort is diverse and
474 covers persons at high risk for both COVID-19 and cardiovascular disease. Thus, the study provides
475 valuable data that indicate that myocardial cell injury and endothelial dysfunction is not a common
476 feature of COVID-19 vaccination and was not detectable up to 4 weeks after the 1st and 2nd
477 homologous (BNT/BNT) or heterologous (AZ/BNT) COVID-19 vaccination. Hence, based on our data

478 and other available evidence, a general cardiovascular peri-vaccine monitoring is not needed.
479 However, based on the three individual cases of observed temporal subclinical troponin elevation,
480 and one HCW case of persistent hsTnT rise, it should be further investigated if males under the age of
481 40, who suffer from pre-existing cardiovascular conditions or previously documented increase in
482 hsTnT levels would benefit from active troponin surveillance following COVID-19 vaccination.
483 However, since the vast majority of the population worldwide has had antigenic experience, often via
484 multiple doses of vaccines and infections, generalization of our findings to boosters and re-
485 vaccinations needs to be cautioned. Future research is needed and as of now, all available safety data
486 underscore the excellent safety and very good risk-benefit ratios of COVID-19 vaccines.

487 **Acknowledgements:**

488 We thank all study participants of the EICOV, COVIMMUNIZE, COVIM, COVIM-Boost and BIC-
489 1 study. We also thank all members of the EICOV/COVIM Study Group for sample acquisition and
490 processing: Y. Ahlgrimm, B. Al-Rim, L. Bardtke, K. Behn, N. Bethke, H. Bias, D. Briesemeister, C.
491 Conrad, V. M. Corman, C. Dang-Heine, S. Dieckmann, D. Frey, J.-A. Gabelich, J. Gerdes, U. Gläser, A.
492 Hetey, L. Hasler, E. T. Helbig, A. Horn, C. Hülso, S. Jentzsch, C. von Kalle, L. Kegel, A. Krannich, W.
493 Koch, P. Kopankiewicz, P. Kroneberg, I. Landgraf, L. J. Lippert, M. Lisy, C. Lüttke, P. de Macedo
494 Gomes, B. Maeß, J. Michel, F. Münn, A. Nitsche, A.-M. Ollech, C. Peiser, A. Pioch, C. Pley, K. Pohl, A.
495 Richter, M. Rönnefarth, C. Rubisch, L. Ruby, A. Sanchez Rezza, I. Schellenberger, V. Schenkel, J.
496 Schlesinger, S. Schmidt, S. Schwalgun, G. Schwanitz, T. Schwarz, S. Senaydin, J. Seybold, A.-S.
497 Sinnigen, A. Solarek, A. Stege, S. Steinbrecher, P. Stubbemann, C. Thibeault and D. Treue.

498 **Sources of funding:**

499 The study was funded by “Forschungsnetzwerk der Universitätsmedizin zu COVID-19”, the
500 Federal Ministry of Education and Research (BMBF), Zalando SE, the Federal Institute for Drugs and
501 Medical Devices and intramural funds of Charité - Universitätsmedizin Berlin. The BIC-1 study was

502 performed in collaboration with the Heidelberg university hospital. The funders of the study had no
503 role in study design, data collection, data analysis, data interpretation, or writing of the report.

504 **Disclosures:**

505 Relating to this specific work, all authors have no conflict of interest to declare. Independent
506 of this work, M.M. received speakers and consulting fees from Bayer Healthcare, BMS, Boehringer
507 Ingelheim, Daiichi Sankyo, Astra Zeneca, Sanofi, BRAHMS GmbH and Roche Diagnostics. He received
508 research funding from German public funding authorities for Health Care Research and Roche
509 Diagnostics. S.P. receives research funding from Roche Diagnostics.

510 **Data availability statement:**

511 Data can be available upon reasonable request.

512 **References:**

- 513 1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year
514 of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis.* 2022;22(9):1293-302.
- 515 2. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness
516 of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A
517 systematic review and meta-analysis. *Front Public Health.* 2022;10:873596.
- 518 3. University of Oxford. Coronavirus (COVID-19) vaccinations. 2023. Available from:
519 <https://ourworldindata.org/covid-vaccinations>. Last accessed: 04 August 2023.
- 520 4. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-
521 19 Vaccination. 2023. Available from: [https://www.cdc.gov/coronavirus/2019-
522 ncov/vaccines/safety/adverse-events.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html). Last accessed: 04 August 2023.
- 523 5. European Medicines Agency. Safety of COVID-19 vaccines. 2023. Available from:
524 [https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-
525 disease-covid-19/covid-19-medicines/safety-covid-19-
526 vaccines#:~:text=Reports%20of%20suspected%20side%20effects,-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=Reports%20of%20suspected%20side%20effects,-)

- 527 [Information%20on%20reports&text=Almost%20768%20million%20vaccine%20doses,every%20100%](#)
528 [20administered%20vaccine%20doses](#). Last accessed: 04 August 2023.
- 529 6. ICMRA. ICMRA statement on the safety of COVID-19 vaccines. Available from:
530 https://icmra.info/drupal/strategicinitiatives/vaccines/safety_statement. Last accessed: 07 February
531 2024.
- 532 7. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19
533 Vaccination in a Large Health Care Organization. *N Engl J Med*. 2021;385(23):2132-9.
- 534 8. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and
535 pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
536 *Lancet*. 2022;399(10342):2191-9.
- 537 9. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence,
538 biomarkers, mechanisms and potential therapies. *Acta Pharmacol Sin*. 2023;44(4):695-709.
- 539 10. Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, et al. Adverse events following
540 COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and
541 thrombocytopenia. *Immun Inflamm Dis*. 2023;11(3):e807.
- 542 11. Paknahad MH, Yancheshmeh FB, Soleimani A. Cardiovascular complications of COVID-19
543 vaccines: A review of case-report and case-series studies. *Heart Lung*. 2023;59:173-80.
- 544 12. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L. Incidence, risk
545 factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following
546 covid-19 vaccination: living evidence syntheses and review. *BMJ*. 2022;378:e069445.
- 547 13. Husby A, Hansen JV, Fosbol E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2
548 vaccination and myocarditis or myopericarditis: population based cohort study. *BMJ*.
549 2021;375:e068665.
- 550 14. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases Reported
551 After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*.
552 2022;327(4):331-40.

- 553 15. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis
554 Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA*
555 *Cardiol.* 2021;6(10):1202-6.
- 556 16. Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A,
557 Mansanguan C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in
558 Adolescents. *Trop Med Infect Dis.* 2022;7(8).
- 559 17. Levi N, Moravsky G, Weitsman T, Amsalem I, Bar-Sheshet Itach S, Algur N, et al. A prospective
560 study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy
561 persons. *Eur J Heart Fail.* 2023;25(2):313-8.
- 562 18. Buergin N, Lopez-Ayala P, Hirsiger JR, Mueller P, Median D, Glarner N, et al. Sex-specific
563 differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. *Eur J*
564 *Heart Fail.* 2023.
- 565 19. Levi N, Hasin T. Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot
566 thickens. *Eur J Heart Fail.* 2023;25(10):1882-3.
- 567 20. Terentes-Printzios D, Gardikioti V, Solomou E, Emmanouil E, Gourgouli I, Xydis P, et al. The
568 effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness. *Hypertens*
569 *Res.* 2022;45(5):846-55.
- 570 21. Gregoriano C, Koch D, Kutz A, Haubitz S, Conen A, Bernasconi L, et al. The vasoactive peptide
571 MR-pro-adrenomedullin in COVID-19 patients: an observational study. *Clin Chem Lab Med.*
572 2021;59(5):995-1004.
- 573 22. Smith C. The structural vulnerability of healthcare workers during COVID-19: Observations on
574 the social context of risk and the equitable distribution of resources. *Soc Sci Med.* 2020;258:113119.
- 575 23. Liu E, Dean CA, Elder KT. Editorial: The impact of COVID-19 on vulnerable populations. *Front*
576 *Public Health.* 2023;11:1267723.

- 577 24. Mockel M, Koehler K, Anker SD, Vollert J, Moeller V, Koehler M, et al. Biomarker guidance
578 allows a more personalized allocation of patients for remote patient management in heart failure:
579 results from the TIM-HF2 trial. *Eur J Heart Fail.* 2019;21(11):1445-58.
- 580 25. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC
581 Guidelines for the management of acute myocardial infarction in patients presenting with ST-
582 segment elevation: The Task Force for the management of acute myocardial infarction in patients
583 presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.*
584 2018;39(2):119-77.
- 585 26. Barbier CE, Themudo R, Bjerner T, Johansson L, Lindahl B, Venge P, et al. Cardiac troponin I
586 associated with the development of unrecognized myocardial infarctions detected with MRI. *Clin*
587 *Chem.* 2014;60(10):1327-35.
- 588 27. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and Impact
589 of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol.*
590 2020;76(5):533-46.
- 591 28. Orlev A, Klempfner R, Rott D. Serum Cardiac Troponin T Levels in Asymptomatic Elderly
592 Nursing Home Residents. *Am J Med.* 2018;131(7):842-5.
- 593 29. Sedighi SM, Fulop T, Mohammadpour A, Nguyen M, Prud'Homme P, Khalil A. Elevated
594 Cardiac Troponin Levels in Geriatric Patients Without ACS: Role of Comorbidities. *CJC Open.*
595 2021;3(3):248-55.
- 596 30. Herman DS, Kavsak PA, Greene DN. Variability and Error in Cardiac Troponin Testing: An
597 ACLPS Critical Review. *Am J Clin Pathol.* 2017;148(4):281-95.
- 598 31. Lan NSR, Bell DA. Revisiting the Biological Variability of Cardiac Troponin: Implications for
599 Clinical Practice. *Clin Biochem Rev.* 2019;40(4):201-16.
- 600 32. Abraham N, Spruin S, Rossi T, Fireman B, Zafack J, Blaser C, et al. Myocarditis and/or
601 pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of
602 BNT162b2 and mRNA-1273 vaccines. *Vaccine.* 2022;40(32):4663-71.

603 33. Siddiqi HK, Libby P, Ridker PM. COVID-19 - A vascular disease. Trends Cardiovasc Med. 2021;31(1):1-5.


605 34. Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep. 2012;9(3):244-51.

607 35. Theuerle J, Farouque O, Vasanthakumar S, Patel SK, Burrell LM, Clark DJ, Al-Fiadh AH. Plasma endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular outcomes in humans. Int J Cardiol. 2019;291:168-72.

610

611 **Figures and figure legends:**

612 **Structured graphical abstract:**



613


614

615 Summary of the vaccination scheme and visiting points in the study population (of HCWs and seniors
616 > 70 years) between the 12th of January and the 30th of November 2021. The results showed no
617 overall subtle, chronic myocardial or vascular involvement in our COVID-19 vaccinated cohorts.

618 **Abbreviations:** AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
 619 messenger ribonucleic acid vaccine from BioNTech, EDTA Ethylenediaminetetraacetic acid, HCWs
 620 health care workers, hsTnT high-sensitive troponin T, mid-regional pro-adrenomedullin, V₁-V₃ visiting
 621 times 1-3, w week(s).

622

623 **Figure 1.**



624

625

626 Study population diagram. Recruitment of vulnerable study population with cohort 1 including health
 627 care workers and cohort 2 including elderly general practitioner patients. Vaccinations with either a
 628 heterogenous combination of AZ/BNT or a homologous scheme of BNT/BNT were applied and three
 629 main visits V₁ to V₃ were performed.




630 * One hospital employee of the BNT/BNT cohort did not participate in the enrolment visit V₁ but
 631 received both BNT vaccinations regularly and took part in the visits V₂, V₃ and is, therefore, included
 632 in this study.

633 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2

634 messenger ribonucleic acid vaccine from BioNTech, V₁-V₅ visiting times 1-5, w week(s).

635

636 **Figure 2.**




637

638 **A.** HsTnT values at the three main visiting points for participants of the AZ/BNT and BNT/BNT group
639 (HCWs and elderly), separated by sex. The red dashed line indicates the 14 ng/L threshold. **B.** Box
640 plots of the change of hsTnT values between each visiting time (V_1 - V_2 , V_1 - V_3 , V_1 - V_3), separated by
641 AZ/BNT and BNT/BNT group. **C.** Box plots of the change of hsTnT values between each visiting time
642 (V_1 - V_2 , V_1 - V_3 , V_1 - V_3), separated by AZ/BNT, HCW BNT/BNT and senior BNT/BNT group.

643 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
644 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, V_1 - V_3 visiting
645 times 1-3.

646

647 **Figure 3.**



648

649 Box plots of hsTnT levels of the reference group (orange) compared to the AZ/BNT group (blue) and
650 the BNT/BNT group (HCWs: green; elderly: red) at V_1 to V_3 . The red dashed line indicates the 14 ng/L
651 threshold.

652 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
653 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, V₁-V₃ visiting
654 times 1-3.

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669




670

671

672

673 **Figure 4.**

674



675

676 **A.** MR-proADM values at the three main visiting points for participants of the AZ/BNT and BNT/BNT
 677 group (including HCWs and elderly), separated by sex. The red dashed line indicates the 0.75 nmol/L
 678 threshold. **B.** Box plots of the change of MR-proADM values between each visiting time (V_1 - V_2 , V_1 - V_3 ,
 679 V_1 - V_3).

680 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
 681 messenger ribonucleic acid vaccine from BioNTech, MR-proADM mid-regional pro-adrenomedullin,
 682 V_1 - V_3 visiting times 1-3.

683

684 **Tables and table legends:**

685 **Table 1.** Baseline characteristics of the study cohort and reference group.

Characteristics	COVIM study					BIC-1 study
	All participants	AZ/BNT	BNT/BNT			Reference group
			In total	HCWs	elderly	
Numbers (n)	162	74	88	68	20	300
<i>Patient characteristics</i>						
Age, years [#]	35.6 (30.0-54.1)	33.2 (29.7-45.3)	37.6 (31.1-59.6)	34.2 (29.7-44.0)	83.7 (80.7-87.0)	39.0 (33.0-46.0)
Sex, female	90 (56%)	41 (55%)	49 (56%)	34 (50%)	15 (75%)	150 (50%)
BMI, kg/m ² # 1	23.9 (21.5-25.8)	23.9 (21.7-25.7)	23.8 (21.3-26.1)	24.1 (21.6-26.1)	23.2 (21.5-26.0)	24.9 (22.4-27.7)
Former smokers	6/148 (4.0%)	2/72 (2.7%)	4/76 (5.2%)	4/56 (7.14%)	0/20 (0%)	61/300 (20.3%)
Current smokers	10/148 (6.7%)	4/72 (5.5%)	6/76 (7.8%)	5/56 (8.9%)	1/20 (5%)	105/300 (35.0%)
<i>Comorbidities*</i>						
Cardiovascular diseases	21/162 (13.0%)	4/74 (5.4%)	17/88 (19.3%)	3/68 (4.4%)	14/20 (70%)	n. a.
Hypertonus	20/162 (12.3%)	4/74 (5.4%)	16/88 (18.2%)	3/68 (4.4%)	13/20 (65%)	

Heart insufficiency	4/162 (2.5%)	0	4/88 (4.5%)	0	4/20 (20%)	
Heart rhythm disorder	3/162 (1.9%)	0	3/88 (3.4%)	0	3/20 (15%)	
Myocardial infarction, Angina pectoris, peripheral artery disease, carotid stenosis	3/162 (1.95%)	0	3/88 (3.4%)	0	3/20 (15%)	
Chronic lung diseases	10/162 (6.2%)	4/74 (5.4%)	6/88 (6.8%)	4/68 (5.9%)	2/20 (10%)	
Asthma	6/162 (3.7%)	3/74 (4.1%)	3/88 (3.4%)	3/68 (4.4%)	0	
Chronic Bronchitis	1/162 (0.6%)	0	1/88 (1.1%)	1/68 (1.5%)	0	
COPD	3/162 (1.9%)	1/74 (1.4%)	2/88 (2.3%)	0	2/20 (10%)	
Kidney diseases	7/162 (4.3%)	1/74 (1.4%)	6/88 (6.8)	0	6/20 (30%)	
Cancer	7/162 (4.3%)	3/74 (4.1%)	4/88 (4.5%)	1/68 (1.5%)	3/20 (15%)	
Pre-medication*						
Immunosuppression	9/162 (5.6%)	2/74 (2.7%)	7/88 (8.0%)	3/68 (4.4%)	4/20 (20%)	n. a.
Corticosteroids	4/162 (2.5%)	1/74 (1.4%)	3/88 (3.4%)	0	3/20 (15%)	
Antihypertensive drugs	14/162 (8.6%)	2/74 (2.7%)	12/88 (13.6%)	1/68 (1.5%)	11/20 (55%)	
Anticoagulants	3/162 (1.9%)	0	3/88 (3.4%)	0	3/20 (15%)	
Antiplatelet drugs	4/162 (2.5%)	0	4/88 (4.5%)	0	4/20 (20%)	
Baseline biomarker values						
hsTnT (V ₁ , V _{R-1}), ng/dl [#]	5 (4-7)	4 (4-6)	5 (4-8)	5 (4-6)	18 (11-29)	3.6 (3.0-4.9)
MR-proADM (V ₁), nmol/L [#]	0.44 (0.40-0.55)	0.43 (0.39-0.47)	0.49 (0.42-0.63)	0.44 (0.40-0.54)	0.95 (0.65-1.01)	n. a.

686

687 *: more than one choice possible. #: median with interquartile range (IQR). N.a.: not applicable. ¹ BMI

688 values were available 147 participants in total with 73 AZ/BNT individuals and 74 BNT/BNT people.

689 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BMI Body-Mass-
 690 Index, BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, COPD Chronic Obstructive
 691 Pulmonary Disease, hsTnT high-sensitive troponin T, MR-proADM mid-regional pro-adrenomedullin.

692

693 **Table 2.** Mixed-effects regression models for the course of hsTnT and MR-proADM in HCWs with
 694 visits as repeated measurements and random effects for the intercept. All other variables are treated
 695 as fixed effects.

Parameter	hsTnT		MRproADM	
	β (95% CI)	p	β (95% CI)	p
intercept	1.922 (0.66;3.184)	0.003	0.289 (0.238;0.341)	<0.001
BNT/BNT vaccination (ref. AZ/BNT)	0.362 (-0.287;1.011)	0.272	0.013 (-0.014;0.04)	0.341
age (per 10 years)	0.599 (0.309;0.890)	<0.001	0.045 (0.033;0.057)	<0.001
male sex	1.162 (0.427;1.896)	0.002	-0.011 (-0.038;0.016)	0.407
V ₂ (ref. V ₁)	0.41 (0.124;0.696)	0.005	0.007 (-0.003;0.018)	0.178
V ₃ (ref. V ₁)	0.135 (-0.152;0.421)	0.356	0.009 (-0.002;0.021)	0.120

696

697 Abbreviations: BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, CI confidence
 698 interval, hsTnT high-sensitive troponin T, MR-proADM mid-regional pro-adrenomedullin, ref.
 699 reference to, V₁-V₃ visiting times 1-3, 95% CI 95% confidence interval.

700


701

702

703

704 **Appendices:**

705 **Supplementary figure 1.**



706

707 Study population diagram of the follow-up study COVIM-Boost. A 3rd (and optionally 4th) vaccination
 708 was done and visit data was collected at V₄ and V₅.

709 Abbreviations: BNT BNT162b2 messenger ribonucleic acid vaccine from BioNTech, MOD messenger
 710 ribonucleic acid -1273 vaccine from Moderna, V₁-V₅ visiting times 1-5, w week(s).

711

712

713


714

715


716

717 **Supplementary figure 2. A.** HsTnT values at all six visiting points (including the follow ups) for
718 participants of the AZ/BNT and BNT/BNT group (HCWs and elderly), separated by sex.

A



B




719

720 The red dashed line indicates the 14 ng/L threshold. **B.** Box plots of the change of hsTnT values
721 between each visiting time (V_1-V_2 , V_1-V_3 , V_1-V_3).

722 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
723 messenger ribonucleic acid vaccine from BioNTech, HCW health care workers, hsTnT high-sensitive
724 troponin T.

725 **Supplementary figure 3.** MR-proADM values at the five visiting points (V_1 - V_5) for participants of the
726 AZ/BNT and BNT/BNT group (including HCWs and elderly), separated by sex.



727

728 The red dashed line indicates the 0.75 nmol/L threshold.

729 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
730 messenger ribonucleic acid vaccine from BioNTech, MR-proADM mid-regional pro-adrenomedullin,
731 V_1 - V_5 visiting times 1-5.

732

733

734

735


736

737

738

739

740 **Supplementary figure 4.** The correlation scatter plots are presented separately for sex with
741 Spearman correlation coefficients. **A)** Correlation between hsTnT and MR-proADM values at all 3
742 visits. **B)** Correlation between age and MR-proADM levels at V₁. **C)** Correlation between age and
743 hsTnT levels at V₁.



744

745 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2
746 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, MR-proADM
747 mid-regional pro-adrenomedullin.

748

749

750

751

752 **Supplementary table 1.** Mixed-effects regression models for propensity score-matched groups.

Parameter	hsTnT		MRproADM	
	β (95% CI)	p	β (95% CI)	p
intercept	2.161 (0.954;3.367)	<0.001	0.320 (0.270;0.370)	<0.001
BNT/BNT vaccination (ref. AZ/BNT)	0.335 (-0.026;0.697)	0.069	0.014 (-0.001;0.029)	0.067
age (per 10 years)	0.555 (0.276;0.833)	<0.001	0.037 (0.025;0.048)	<0.001
male sex	1.391 (0.905;1.878)	<0.001	-0.012 (-0.032;0.008)	0.229
V ₂ (ref. V ₁)	0.440 (-0.001;0.881)	0.050	0.007 (-0.010;0.025)	0.391
V ₃ (ref. V ₁)	0.139 (-0.301;0.580)	0.534	0.007 (-0.011;0.025)	0.453

753

754 Abbreviations: AZ ChAdOx1 nCov-19 adenoviral vector vaccine from Astra Zeneca, BNT BNT162b2

755 messenger ribonucleic acid vaccine from BioNTech, hsTnT high-sensitive troponin T, MR-proADM

756 mid-regional pro-adrenomedullin, ref. reference, V₁-V₃ visiting times 1-3, 95% CI 95% confidence

757 interval.